Cipla Ltd has announced the launch of Nintib, a generic version of Nintedanib capsules for treating Idiopathic Pulmonary Fibrosis, as part of its ongoing commitment to address rare lung diseases. The capsules will be available in two strengths and are priced to enhance patient access to this critical treatment.
Cipla Limited has informed the Exchange regarding a press release dated October 20, 2020, titled "Cipla launches Nintib (Nintedanib capsules 100 mg, 150 mg) to treat Idiopathic Pulmonary Fibrosis, in continuation of its fight against rare lung diseases".